newsfilter
← Latest News
GlobeNewswire·

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the